Clinical Effcicacy of Antiplatelet Combined with Anticoagulation Therapy for Restenosis Prophylaxis after Stent Placement in Diabetic Patients with Leg Atherosclerosis Obliterans
- VernacularTitle:抗血小板联合抗凝治疗预防糖尿病下肢动脉硬化闭塞症支架植入后再狭窄疗效观察
- Author:
Jinhong SUN
;
Jian WANG
;
Jie ZHANG
- Publication Type:Journal Article
- Keywords:
Antiplatelet;
Anticoagulation;
Diabetic leg atherosclerosis obliterans;
Stent placement;
Restenosis
- From:
China Pharmacist
2016;19(5):935-937,938
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of antiplatelet combined with anticoagulation therapy for restenosis prophylaxis after stent placement in diabetic patients with leg atherosclerosis obliterans(LASO). Methods:83 diabetic LASO patients with stent placement were collected and randomly divided into the treatment group(42 cases)and the control group (41 cases)with 49 sick limbs in each. The control group was treated with clopidogrel(75mg,for 1 year)plus bayaspirin(100 mg),while the treatment group was treated with low molecular heparin(withdrawal when INR = 2. 0- 3. 0)plus warfarin(for 6 months)additionally. All cases were followed up for 12 months and the efficacy and safety were compared and evaluated. Results:After therapy,there were no differences in FPG,GHbA1C,TC and LDL-C at each time point between the two groups(P >0. 05). Compared with that in the control group,MLD in the treatment group was improved obviously(P < 0. 05)in the 12th month after the surgery,while restenosis rate and level of D-D in plasma were declined significantly(P < 0. 05). And there was no difference in bleeding rate between the two groups(P > 0. 05). Conclusion:Compared with antiplatelet therapy,antiplatelet combined with anticoagulation therapy for restenosis prophylaxis after stent placement in diabetic LASO patients is more effective and safer,which is worthy of clinical promotion.
